Compare Ascendis Pharma A/S (ASND) vs Paycom Software Inc (PAYC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Paycom Software Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Paycom Software Inc trades at $140.1 (market cap $6.48B). The key difference: Ascendis Pharma A/S is far larger — about 2.7× Paycom Software Inc's market cap, and Paycom Software Inc pays a 1.08% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PAYC | |
|---|---|---|
Market Cap | $17.74B | $6.48B |
Sector | Health | Technology |
52-Week High | $277.18 | $238.80 |
52-Week Low | $163.32 | $113.59 |
Enterprise Value | $18.11B | $7.09B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Paycom Software (PAYC) trades at $139.08, down 0.34% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 22.44% net income margin and 37.15% ROE, though recent Q3 2025 EPS slightly missed expectations. Recent board appointments and industry awards highlight ongoing corporate development. The consensus price target is $151.00, suggesting potential upside from current levels.
The outlook remains balanced with solid fundamentals supporting growth, but risks include competitive pressures and execution challenges. Analyst sentiment is mixed with near-equal buy and hold ratings. Revenue growth stability and margin maintenance are key for sustained investor confidence amid a neutral oscillator signal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
